<DOC>
	<DOCNO>NCT00230490</DOCNO>
	<brief_summary>Compare long-term safety pradefovir adefovir dipivoxyl</brief_summary>
	<brief_title>Open-label Treatment Extension Study Patients Who Complete Study RNA200103-201</brief_title>
	<detailed_description>- Compare long-term safety pradefovir adefovir dipivoxyl - Monitor development resistance - Evaluate virologic biochemical response</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<criteria>Patients complete 48 week treatment study RNA200103201 Patients determine treatment failure study RNA200103201 Patients experience serious adverse event judge related study drug study RNA200103201 Patients serum creatinine great 2.0 mg/dl two consecutive determination study RNA200103201</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Hepatitis B , Chronic</keyword>
	<keyword>Hepatitis B Virus</keyword>
	<keyword>Pradefovir Mesylate</keyword>
	<keyword>Adefovir Dipivoxyl</keyword>
</DOC>